Abstract
Background: Protein farnesyltransferase (PFT) inhibitors have emerged as a potent target for the malaria treatment caused by the Plasmodium falciparum (Pf) parasite.
Objective: To explore the various scaffolds which are active against Pf-PFT target.
Result: Seven inhibitor scaffolds based on ethylenediamine, peptidomimetic, benzophenone, benzamide, tetrahydroquinoline, naphthyridine and oxy-tetrahydroquinoline, have been developed till date.
Conclusion: It is concluded that naphthyridine based drugs are the most promising one. Furthermore, introducing the hydrophobic molecules like isoprenyl groups to a protein or a chemical compound facilitate protein-protein and protein-membrane interactions thereby makes them good candidates as new therapeutics. The future research should focus on the disease rather than the infection and the dynamics of its transmission; this will bring a new vision about the disease.
Keywords: Plasmodium falciparum, antimalarial, protein, farnesyltransferase, inhibitor.
Current Drug Targets
Title:A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets
Volume: 18 Issue: 14
Author(s): Kamlesh Sharma*
Affiliation:
- Department of Chemistry, Faculty of Physical Sciences, Shree Guru Gobind Singh Tricentenary University, Gurugram 122505, Haryana,India
Keywords: Plasmodium falciparum, antimalarial, protein, farnesyltransferase, inhibitor.
Abstract: Background: Protein farnesyltransferase (PFT) inhibitors have emerged as a potent target for the malaria treatment caused by the Plasmodium falciparum (Pf) parasite.
Objective: To explore the various scaffolds which are active against Pf-PFT target.
Result: Seven inhibitor scaffolds based on ethylenediamine, peptidomimetic, benzophenone, benzamide, tetrahydroquinoline, naphthyridine and oxy-tetrahydroquinoline, have been developed till date.
Conclusion: It is concluded that naphthyridine based drugs are the most promising one. Furthermore, introducing the hydrophobic molecules like isoprenyl groups to a protein or a chemical compound facilitate protein-protein and protein-membrane interactions thereby makes them good candidates as new therapeutics. The future research should focus on the disease rather than the infection and the dynamics of its transmission; this will bring a new vision about the disease.
Export Options
About this article
Cite this article as:
Sharma Kamlesh *, A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets, Current Drug Targets 2017; 18 (14) . https://dx.doi.org/10.2174/1389450117666160823165004
DOI https://dx.doi.org/10.2174/1389450117666160823165004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers
Current Cancer Drug Targets Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)
Current Medicinal Chemistry Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Progress and Pitfalls in the Identification of Cancer Stem Cell-Targeting Therapies in Head and Neck Squamous Cell Carcinoma
Current Medicinal Chemistry Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Development of Metal-Based Drugs and Application in Clinical Treatment
The Natural Products Journal